- Home
- ANL vs CRVO Comparison
ANL vs CRVO Comparison
Compare ANL & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- CRVO
- Stock Information
- Founded
- ANL 2004
- CRVO 2001
- Country
- ANL Cayman Islands
- CRVO United States
- Employees
- ANL N/A
- CRVO N/A
- Industry
- ANL
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- ANL
- CRVO Health Care
- Exchange
- ANL Nasdaq
- CRVO Nasdaq
- Market Cap
- ANL 61.8M
- CRVO 67.4M
- IPO Year
- ANL 2023
- CRVO N/A
- Fundamental
- Price
- ANL $1.79
- CRVO $8.50
- Analyst Decision
- ANL Hold
- CRVO Strong Buy
- Analyst Count
- ANL 1
- CRVO 6
- Target Price
- ANL N/A
- CRVO $19.17
- AVG Volume (30 Days)
- ANL 11.3K
- CRVO 92.4K
- Earning Date
- ANL 10-21-2025
- CRVO 11-11-2025
- Dividend Yield
- ANL N/A
- CRVO N/A
- EPS Growth
- ANL N/A
- CRVO N/A
- EPS
- ANL N/A
- CRVO N/A
- Revenue
- ANL N/A
- CRVO $7,776,968.00
- Revenue This Year
- ANL N/A
- CRVO N/A
- Revenue Next Year
- ANL N/A
- CRVO N/A
- P/E Ratio
- ANL N/A
- CRVO N/A
- Revenue Growth
- ANL N/A
- CRVO N/A
- 52 Week Low
- ANL $1.10
- CRVO $1.80
- 52 Week High
- ANL $3.89
- CRVO $16.94
- Technical
- Relative Strength Index (RSI)
- ANL 55.55
- CRVO 51.94
- Support Level
- ANL $1.70
- CRVO $7.90
- Resistance Level
- ANL $1.82
- CRVO $8.93
- Average True Range (ATR)
- ANL 0.09
- CRVO 0.42
- MACD
- ANL -0.00
- CRVO 0.06
- Stochastic Oscillator
- ANL 60.33
- CRVO 84.30
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.